Portfolio

SciRhom

SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge bench research and the completion of a challenging, yet ultimately successful antibody campaign, SciRhom is now in the unique position to pursue the development of monoclonal antibodies against iRhom2 for the treatment of major autoimmune diseases.

Info & Contact

Dr. Jens Ruhe
Web:
scirhom.com

Address

Am Klopferspitz 19
82152 Planegg/Martinsried
Deutschland

In portfolio

27. Oct 2016